Top Markets
Coin of the day
Health-Chem Corporation Health-Chem Corporation

Health-Chem Corporation

HCLC
Rang in aandelen #40841
Health-Chem Corporation, operating through its subsidiary, Transderm... Health-Chem Corporation, operating through its subsidiary, Transderm Laboratories Corporation, specializes in the research, development, manufacturing, and commercialization of transdermal drug delivery systems throughout the United States. Among its key products are transdermal nitroglycerin patches, formulated to provide relief for vascular and cardiovascular symptoms linked to angina pectoris (commonly known as chest pain) via skin absorption. The company additionally offers contract research and development services to third-party clients. Health-Chem Corporation employs a multifaceted sales strategy, directly engaging with wholesalers, distributors, prominent retail pharmacy chains, mail-order pharmacies, and group purchasing organizations. Its products also reach the market indirectly through independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management firms. Founded in 1970, the company's headquarters are situated in Emigsville, Pennsylvania.
Aandeelprijs
$0.0001
Laatst gesynchroniseerd: 2025-01-02
Marktkapitalisatie
$73.99K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Health-Chem Corporation (HCLC)

Categorie

Winst voor Health-Chem Corporation (HCLC)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Health-Chem Corporation bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Health-Chem Corporation van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US